Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Does Inotiv, Inc. (NOTV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy?

Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Inotiv (NOTV) Stock?

Photronics

RADCOM

In between the noise, fear of missing out and hype in stock markets, specific opportunities usually slip under the radar. These overlooked stocks move within the depths of lesser-known layers of the market.

3 Overlooked Stocks with Potential for 500% Growth by 2025

Forestar Group

Rowan Cos. Plc

In the vast opportunities, certain stocks emerge as hidden gems, promising solid returns and the potential to redefine and deliver historic gains. The article lists three game-changing stocks and the companies at the edge of their industry progress.

Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains

Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum

Are Investors Undervaluing Inotiv (NOTV) Right Now?

Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of $0.07. This compares to loss of $1.28 per share a year ago.

Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates

Inotiv, Inc. (NOTV) Q1 2024 Earnings Call Transcript

- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus on sales and marketing as near-term infrastructure projects near completion - Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2024”) ended December 31, 2023.

Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inotiv, Inc. (NASDAQ: NOTV) on behalf of long-term stockholders following a class action complaint that was filed against Inotiv on June 23, 2022 with a Class Period from September 21, 2021 to November 16, 2022. Our investigation concerns whether the board of directors of Inotiv have breached their fiduciary duties to the company. The litigat.

INOTIV ALERT: Bragar Eagel & Squire, P.C. is Investigating Inotiv, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NOTV stock has significantly dropped due to a supply chain shock, but the current price remains far below its estimated fair value. The company's fundamental recovery is in place, with strong financial performance and positive guidance for 2024. The stock price is lagging behind the company's performance, creating an opportunity for investors to potentially make 3-5x returns.

Inotiv: The Business Is Recovering, The Stock Will Follow

Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock

Inotiv, Inc. (NASDAQ:NOTV ) Q4 2023 Earnings Conference Call December 11, 2023 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors, Investor Relations Bob Leasure - Chief Executive Officer, President, and Director Beth Taylor - Senior Vice President of Finance and Chief Financial Officer Conference Call Participants Tim Daley - Wells Fargo Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv's Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Inotiv, Inc. (NOTV) Q4 2023 Earnings Call Transcript

— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing expected to drive continued growth of fiscal 2024 DSA revenues— Anticipate achieving the balance of expected expense reductions in fiscal 2024— Conference call begins today at 4:30 pm ET

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

WEST LAFAYETTE, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will be partnering with Vanguard Supply Chain Solutions LLC, the Company's current provider of transportation services, to enable the in-house integration of Inotiv's North American transportation operations.

Inotiv, Inc. Announces Plan to Insource North American Transportation Operations

WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, on Monday, December 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023

WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provides business updates related to Inotiv's operations and an update regarding its participation in upcoming investor conferences.

Inotiv Provides Business Updates and Upcoming Investor Conferences Update

Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint

Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.

Inotiv, Inc. to Participate in Upcoming Investor Conferences

WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board.

Inotiv, Inc. Announces Changes to its Board Composition

NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inotiv, Inc. ("Xylem" or the "Company") (NASDAQ: NOTV). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inotiv, Inc. - NOTV

WEST LAFAYETTE, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the completion of the sale of its businesses in Israel. The sale complements Inotiv's site optimization plan for the Research Models and Services segment of the business.

Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd.

WEST LAFAYETTE, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout September 2023.

News for Inotiv, Inc. Stock (NOTV)